-

Deep Genomics to Present at the 40th Annual J.P. Morgan Healthcare Conference

TORONTO & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Deep Genomics, the leading AI RNA therapeutics company, today announced that its Founder and CEO, Brendan Frey, PhD, FRSC, will present at the 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022, at 10:00 a.m. EST.

The presentation will be available as a live webcast through the J.P. Morgan Healthcare Conference portal.

About Deep Genomics

Deep Genomics combines artificial intelligence (AI) and RNA biology to program and prioritize transformational AI-enabled therapies for almost any gene in any genetic condition. The proprietary platform, called the AI Workbench, allows Deep Genomics to decode vast amounts of data on RNA biology, identify novel targets for genetic diseases, and produce therapeutic programs with a high success rate. Almost everyone will suffer from a genetic condition at some point in their life, and Deep Genomics aims to be there for them with a genetically precise therapy. Deep Genomics is located in Toronto, Ontario, and Cambridge, Massachusetts. For more information, visit www.deepgenomics.com and follow us on LinkedIn and Twitter.

Contacts

Adam Silverstein
adam@scientpr.com

Industry:

Deep Genomics

Release Versions
English

Contacts

Adam Silverstein
adam@scientpr.com

Social Media Profiles
Deep Genomics
More News From Deep Genomics

Tal Zaks Joins Strategic Advisory Board at Deep Genomics

TORONTO & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Deep Genomics, the leading AI therapeutics company, welcomes Tal Zaks, MD, PhD, to its Strategic Advisory Board, effective today. Deep Genomics uses AI and machine learning to program and prioritize transformational nucleotide-based therapeutics for genetic diseases. As Chief Medical Officer at Moderna, Zaks successfully led a team that pioneered the field of mRNA therapeutics and drove extraordinary growth, with more than two dozen preclinical and c...

Deep Genomics Raises $180M in Series C Financing

TORONTO--(BUSINESS WIRE)--Deep Genomics, the leading artificial intelligence (AI) therapeutics company, announced today the closing of a $180 million Series C financing round. SoftBank Vision Fund 2* led the financing with participation from new investors, Canadian Pension Plan Investment Board (CPP Investments), Fidelity Management & Research Company LLC, Alexandria Venture Investments, and existing investors Amplitude Ventures, Khosla Ventures, Magnetic Ventures, and True Ventures. Deep G...

Deep Genomics to Participate in Citi PCA – Private Company Digital Health Conference

TORONTO--(BUSINESS WIRE)--Deep Genomics, the leading artificial intelligence (AI) therapeutics company, announced today that its Founder and Chief Executive Officer, Brendan Frey, Ph.D., F.R.S.C., will participate in a panel discussion during the Citi PCA – Private Company Digital Health Conference *VIRTUAL* on May 20, 2021. Details: Session: Artificial Intelligence in Drug Discovery Date and time: Thursday, May 20, 2021 from 1:30 – 2:00 p.m. EDT About Deep Genomics Deep Genomics is pioneering...
Back to Newsroom